- $4.05bn
- $3.45bn
- $1.11bn
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million
Alkermes climbs as Evercore upgrades stock to 'outperform'
Alkermes Plc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Alkermes Presents First Clinical Data For Orexin 2 Receptor Agonist Alks 2680
U.S. STOCKS ON THE MOVE-Vera Bradley, Apple, Salesforce
U.S. STOCKS ON THE MOVE-Energy firms, Gold miners, Tingo group
Alkermes soars after settling patent litigation with Teva
Brief: Alkermes Announces Settlement With Teva Related To Vivitrol Patent Litigation
Alkermes Plc reports results for the quarter ended in June - Earnings Summary
Brief: Alkermes Q2 Revenue USD 617.4 Million Vs. IBES Estimate USD 585 Million
Alkermes Plc expected to post earnings of 56 cents a share - Earnings Preview
Brief: Alkermes Re-Elects All Seven Company Director Nominees At Annual General Meeting
Alkermes beats back board room challenge from Sarissa Capital Management, all directors re-elected - sources (updated)
Alkermes beats back board room challenge from Sarissa Capital Management, all directors re-elected - source
Brief: Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger
ISS recommends one of Sarissa's three nominees for Alkermes board